## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. PE: 10/771,330
Applicant: Edward M. LANE

Filed / February 5, 2004

TC/A: U. AUG 3 0 2005 = 1614

Examiner To Be Assigned

Customer No. : 3030-109 Confirmation No. : 2562

## INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

## Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. The references submitted herein were cited in an International Search Report for a related application dated June 16, 2005. Applicants believe that no fee is due for this submission, however if the Office deems a fee necessary, the Office is authorized to charge our deposit account number 02-2135.

	F	RESPECTFULL	Y SUBMITTED	,	
NAME AND REG. NUMBER	Martha Ca Reg. No.		>		<del></del>
SIGNATURE	1	~~	DA	TE 8/2	80/05
Address		igg, Ernst &			
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

				Complete if Known		
				Application Number	10/771,330	
INFORMAT	TION DISC	LOSU	RE	Filing Date	February 5, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Edward M. LANE	
Alle 3 a ann	•			Group Art Unit	1614	
AUG 3 0 2005 =	3			Examiner Name	To Be Assigned	
PADEMARK CHIEF				Confirmation No.	2562	
Sheet	1	of	3	Attorney Docket Number	3030-109	

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Doo	Kind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
	1	4,938,959		MARTIN et al.	07-03-1990				
	2	6,235,722	B1	· JAYAPATHY	05-22-2001				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

				Complete if Known		
				Application Number	10/771,330	
INFORMA <sup>*</sup>				Filing Date	February 5, 2004	
STATEME	NT BY API	PLICA	NT	First Named Inventor	Edward M. LANE	
				Group Art Unit	1614	
				Examiner Name	To Be Assigned	
				Confirmation No.	2562	
Sheet	Sheet 2 of 3				3030-109	

			FOR	EIGN PATE	ENT DOCUMENTS		
Examiner Initials*	Cite No.1	Office <sup>3</sup>	eign Patent Docun	Kind⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
IIIIIais	INU.	Code		(if known)	of Cited Document	IVIIVI-DD-1111	
	3	EP	0 555 898	A2	FIDIA S.p.A.	08-18-1993	
	4	JP	10 212234	A	. Izumiya, Ken	08-11-1998	AB
_							
<del>-</del> -			<u>.</u>				
			<del></del>				
	<u> </u>		<del>.</del>		<u> </u>		<u> </u>
Examiner Signature			·		Date Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

				Complete if Known		
				Application Number	10/771,330	
	ATION DISC			Filing Date	February 5, 2004	
STATEM	STATEMENT BY APPLICANT			First Named Inventor	Edward M. LANE	
				Group Art Unit	1614	
				Examiner Name	To Be Assigned	
				Confirmation No.	2562	
Sheet	3	of	3	Attorney Docket Number	3030-109	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	5	BELLINI et al., Malignant Otitis Externa Due To Aspergillus Niger," Scand. J. Infec. Dis., 35(4):284-288, 2003.						
	6	BHALLY et al., "Otitis Caused by Scedosporium apiospermum in an Immunocompetent Child," Int'l. J. Pediatric Otorhinolaryngology, 68:975-978, 2004.						
	7	CLARK, R. F., "Chromoblastomycosis of the Ear: Successful Intralesional Therapy with Amphotericin B," <i>Cutis</i> , 24(3):326-328, 1979.						
	8	DEKA et al., "Chronic Otitis Media-A Clinical and Bacteriological Study," The Eye, Ear, Nose and Throat Monthly, 54(5):198-201, 1975.						
	9	HANNLEY et al., "Consensus Panel Report: Use of Ototopical Antibiotics in Treating 3 Common Ear Diseases," Otolaryngology-Head and Neck Surgery, 122(6):934-940, 2000.						
	10	IKEDA et al., "Topical Treatment of Otomycosis with Fluconazole," <i>Practica Otologica</i> , 87(2):283-287, 1994.						
	11	ITOH et al., "A Neutropenic Acute Myeloid Leukemia Patient Complicated with Chronic Otitis Media Due to Aspergillus Niger and Yeast-Like Fungi Caused by Superinfection," J. Japanese Assoc. Infec. Dis., 73(6):618-622, 1999.	АВ					
	12	JADHAV et al., "Etiological Significance of Candida Albicans in Otitis Externa," Mycopathologia, 156(4):313-315, 2003.						
	13 KINTZEL et al., "Otic Administration of Amphotericin B 0.25% In Sterile Water," Ann. Pharmacotherapy, 28:333-335, 1994.							
	14	KUMAR et al., "Treatment of Otitis Externa in Dogs Associated With Malassezia Pachydermatis," Indian Vet. J., 79:727-729, 2002.						
	15 MERCK & Co., "Merck Index," Therapeutic Category and Biological Activity Index, Ther-9, Cols., 2-3, 2001.							
	MORRIS, D.O., "Medical Therapy of Otitis Externa and Otitis Media," Vet. Clin. N. Amer. Small. Ani Pract., 34:541-555, 2004.							
	17	NIELSEN, "Fungi Isolated from Chronic External Ear Disorders," Mykosen, 28(5): 234-237, 1985.						
·	18	STUDDERT et al., "A Clinical Trial of a Topical Preparation of Miconazole, Polymyxin and Prednisolone in the Treatment of Otitis Externa in Dogs," <i>Australian Vet. J.</i> , 68(6):193-195, 1991.						
Examiner Signature		Date Considered						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.